

(19) [logo] European Patent Office

[bar-code]



(12)

EUROPEAN PATENT APPLICATION

(21) Filing No.: 90-403131.7

(51) Intl. Cl. [international class]⁵: A 23 L
1/30, A 61 K 35/72, A 61 K 35/74

(22) Filing date: November 6, 1990 (06.11.90)

(30) Priority: November 20, 1989
(20.11.89) FR 89-15197

(43) Application publication date: June 5,
1991 (05.06.91), in issue No. 91/23 of
the Bulletin

(84) Designated contracting countries:
BE, CH, ES, IT, LI, LU, NL, SE
Bulletin /sic/ [Belgium,
Switzerland, Spain, Italy,
Liechtenstein, Luxembourg, the
Netherlands, Sweden]

(71) Applicant:
LABORATOIRES DOLISOS
71 rue Beaubourg
F-75003 Paris (France)

(72) Inventor:
François Levy
38, rue Boileau
F-75016 Paris (France)

(74) Agent:
Claude Alexandre Jean Madeuf
CABINET MADEUF
3, avenue Bugeaud
F-75116 Paris (France)

(54) Product having a base of dietary yeasts enabling improved balance
in human and animal organic functions.

(57) [Abstract]

Bifido bifidum bacteria (*Bifidus*) are added to a given quantity of lactic-acid yeast
and/or brewer's yeast.

**PRODUCT HAVING A BASE OF DIETARY YEASTS ENABLING IMPROVED
BALANCE IN HUMAN AND ANIMAL ORGANIC FUNCTIONS.**

The present invention relates to a product having a base of dietary yeasts enabling an improvement in the balance of organic functions in humans as well as in animals.

It is known that lactic-acid yeast and brewer's yeast are dietary yeasts that are rich in proteins, B vitamins, and trace elements. These yeasts encourage the metabolism of carbohydrates and lipids. They are known to have a beneficial effect on the condition of the skin, nails, and hair, as well as on the regulation of intestinal transit. In animals, these yeasts improve the quality of the coat.

The *Bifido bifidum* bacterium (also referred hereinbelow as "*Bifidus*") also has a rebalancing effect on intestinal flora, by slowing the proliferation of undesirable microorganisms in the intestine. *Bifidus* also improves the brightness of the complexion and the quality of the skin.

In a surprising manner, it has now been discovered that a certain combination of such dietary yeasts with *Bifidus* has a synergistic effect and strengthens the balance of organic functions, in humans as well as in animals.

However, it should be noted that prior to this invention, publications were known that described either dietary products or medications that were likewise based on dietary yeasts or brewer's yeast. Consequently, reference is now made specifically to the French document designated as "FR-M-3614", which document relates to an anhydrous composition containing a milk-based product and a malt extract placed inside a substantially anhydrous sugar mass that also contains the dehydrated cultures of various bacteria, which composition in its entirety can be packaged, in any of the standard pharmaceutical forms, for absorption.

In accordance with the invention, the product having a base of dietary yeasts — which product is packaged in the form of chewable tablets, lozenges to be swallowed, or an edible powder or flakes that may optionally be ingested along with food — is characterized in that it includes a proportion of yeasts ranging from approximately 100% lactic-acid yeast and 0% brewer's yeast to 0% lactic-acid yeast and approximately 100% brewer's yeast, to which from 0.002% to 15% *Bifido bifidum* bacteria (*Bifidus*) is added.

However, the proportion of yeasts employed preferably ranges from approximately 50% lactic-acid yeast and 50% brewer's yeast to approximately 1/3 lactic-acid yeast and 2/3 brewer's yeast, to which from 0.02 to 5% *Bifido bifidum* bacteria (*Bifidus*) is added.

Various other characteristics of the invention will also become clear from the following detailed description.

Various embodiments of the subject of the invention are listed hereinbelow as non-limitative examples.

Chewable tablets, which are preferably ingested during meals, have been prepared in accordance with the following formula:

- Lactic-acid yeast: 50%
- Brewer's yeast: 49.998%
- *Bifidus*: 0.002%
- Excipients: in sufficient quantity to make up one tablet

Lozenges to be swallowed, preferably before meals, have been prepared in accordance with the following formula:

- Lactic-acid yeast: 34.98%
- Brewer's yeast: 65%
- *Bifidus*: 0.002%
- Excipients: in sufficient quantity to make up one lozenge

An edible powder, which is preferably ingested in the form of a seasoning for raw vegetables and other appetizers and/or hors d'oeuvres, has been prepared in accordance with the following formula:

- Lactic-acid yeast: 44%
- Brewer's yeast: 51%
- *Bifidus*: 5%
- Excipients: in sufficient quantity to form a powder

Flakes, which are preferably mixed with the yogurt that is consumed at the end of a meal, have been prepared in accordance with the following formula:

- Lactic-acid yeast: 33%
- Brewer's yeast: 57%
- *Bifidus*: 10%
- Excipients: in sufficient quantity to form flakes

Lozenges, which are preferably sucked between meals or while otherwise fasting, have been prepared in accordance with the following formula:

- Lactic-acid yeast: 85%
- *Bifidus*: 15%
- Excipients: in sufficient quantity to form lozenges

A powder that is mixed with water has been prepared in accordance with the following formula:

- Lactic-acid yeast: 99.8%
- *Bifidus*: 0.2%
- Excipients: in sufficient quantity to form a powder

Moreover, despite the fact that the foregoing examples relate to human medicine, the product according to the invention may also be used in animal medicines, in analogous proportions.

In a surprising manner, after a few days of treatment with the aid of the various preparations described hereinabove, an improved balance was observed in the organic functions of human beings or animals that had undergone the treatment, which optionally may have been continued for several months.

In point of fact, this improvement was markedly superior to what might have been expected from a simple juxtaposition of the above-mentioned properties of the dietary yeasts (lactic-acid yeast and/or brewer's yeast) and *Bifido bifidum* bacteria (*Bifidus*), because of the synergy that exists between these products.

CLAIMS

1. Product having a base of dietary yeasts, which product is packaged in the form of chewable tablets, lozenges to be swallowed, or an edible powder or flakes that may optionally be ingested along with food, characterized in that the said product includes a proportion of yeasts ranging from approximately 100% lactic-acid yeast and 0% brewer's yeast to 0% lactic-acid yeast and approximately 100% brewer's yeast, to which from 0.002% to 15% *Bifido bifidum* bacteria (*Bifidus*) is added
2. Product having a base of dietary yeasts, according to Claim 1, characterized in that the said product includes a proportion of yeasts that ranges from approximately 50% lactic-acid yeast and 50% brewer's yeast to approximately 1/3 lactic-acid yeast and 2/3 brewer's yeast, to which from 0.02 to 5% *Bifido bifidum* bacteria (*Bifidus*) is added.
3. Product having a base of dietary yeasts, according to either Claim 1 or Claim 2, characterized in that the said product has the following formula of active ingredients:
 - Lactic-acid yeast: 50%
 - Brewer's yeast: 49.998%
 - *Bifidus*: 0.002%
4. Product having a base of dietary yeasts, according to either Claim 1 or Claim 2, characterized in that the said product has the following formula of active ingredients:
 - Lactic-acid yeast: 34.98%
 - Brewer's yeast: 65%
 - *Bifidus*: 0.02%
5. Product having a base of dietary yeasts, according to either Claim 1 or Claim 2, characterized in that the said product has the following formula of active ingredients:
 - Lactic-acid yeast: 44%
 - Brewer's yeast: 51%
 - *Bifidus*: 5%

6. Product having a base of dietary yeasts, according to either Claim 1 or Claim 2, characterized in that the said product has the following formula of active ingredients:
 - Lactic-acid yeast: 33%
 - Brewer's yeast: 57%
 - *Bifidus*: 10%
7. Product having a base of dietary yeasts, according to either Claim 1 or Claim 2, characterized in that the said product has the following formula of active ingredients:
 - Lactic-acid yeast: 85%
 - *Bifidus*: 15%
 - Excipients: in sufficient quantity to form lozenges
8. Product having a base of dietary yeasts, according to either Claim 1 or Claim 2, characterized in that the said product has the following formula of active ingredients:
 - Brewer's yeast: 99.8%
 - *Bifidus*: 0.2%
 - Excipients: in sufficient quantity to form a powder

EUROPEAN SEARCH REPORT

DOCUMENTS CONSIDERED RELEVANT			CLASSIFICATION OF THE APPLICATION (International Class 5)
Category	Document citation, with an indication, as necessary, of the pertinent portions	Affected claim	
A	FR-M-3,614 (Sigurta) * page 2, column 2, line 4 to page 3, column 2, line 3 *	1	
A	FR-M-6,779 (Blaise) * page 2, column 1, line 4 to page 2, column 2, line 7 *	1	A 23 L 1/30 A 61 K 35/72 A 61 K 35/74
A,E,	WO-A-8,900,425 (Advance) * claims 1, 2, 3, 4, 5, and 6; EP-A-396,744 *	1	
A	US-A-4,251,519 (Robbins et al.) * claim 1 *	1	
A	EP-A-0,181,170 (Advance) * claim 1 *	1	
A	WO-A-8,901,025 (Allnatur Bio-Produkte) * claims 1 and 9 *	1	TECHNICAL FIELDS SEARCHED (International Class 5)
A	FR-M-2,946 (Salvoxyl) * the entire document *	1	A 23 L A 61 [sic] K [sic; the standard syntax would be "A 61 K" - Tr.] A 21 K
The present search report was compiled for all of the claims.			

Search location: The Hague	Search completed on (date): March 7, 1991	Examiner: A.M.J. van Moer
CATEGORIES OF THE CITED DOCUMENTS		
<p>X: Particularly pertinent, in and of itself</p> <p>Y: Particularly pertinent, in combination with another document in the same category</p> <p>A: Pertinent to at least one claim, or to the overall technological background</p> <p>O: Unwritten disclosure</p> <p>P: Intercalary [i.e., inserted] document</p> <p>T: Theory or principle behind the invention</p> <p>E: Patent document bearing a date prior to the filing date, and which was published only on that filing date or on a later date</p> <p>D: Cited in the application</p> <p>L: Cited for other reasons</p> <p>.....</p> <p>&: Member of the same family; corresponding document</p>		